Načítá se...
BH4 domain of Bcl-2 as a novel target for cancer therapy
Overexpression of B cell lymphoma 2 (Bcl-2) proteins is associated with therapy resistance in various human cancers. Traditional approaches target the Bcl-2 homology (BH)3 domain of Bcl-2; however, the BH4 domain represents a superior therapeutic target in light of its unique structure and crucial i...
Uloženo v:
| Vydáno v: | Drug Discov Today |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4882289/ https://ncbi.nlm.nih.gov/pubmed/26631752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2015.11.008 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|